Hengrui Pharmaceutical announced that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration to approve the marketing of Relafulp α injection, a Class 1 innovative drug independently developed by the company. This drug is used in combination with fluorouracil and platinum drugs for first-line treatment of locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma with fully verified tests that evaluate PD-L1 positive. According to inquiries, no similar products have been approved for sale at home or abroad. Up to now, Rilavupu α injection-related projects have invested a total of about 711 million yuan in R&D.

Hengrui Pharmaceutical announced that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration to approve the marketing of Relafulp α injection, a Class 1 innovative drug independently developed by the company. This drug is used in combination with fluorouracil and platinum drugs for first-line treatment of locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma with fully verified tests that evaluate PD-L1 positive. According to inquiries, no similar products have been approved for sale at home or abroad. Up to now, Rilavupu α injection-related projects have invested a total of about 711 million yuan in R&D.